What is the price target for NRX stock?
9 analysts have analysed NRX.CA and the average price target is 3.57 CAD. This implies a price increase of 485.25% is expected in the next year compared to the current price of 0.61.
NUREXONE BIOLOGIC INC (NRX.CA) Forecast, Price Target & Analyst Ratings
TSX-V:NRX • CA67059R1091
Current stock price
0.61 CAD
+0.02 (+3.39%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NUREXONE BIOLOGIC INC (NRX.CA).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- N/A
- Period
- Q1 / 2026
- EPS Estimate
- -$0.02
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
CA$3.57
Upside
+ 485.25%
From current price of CA$0.61 to mean target of CA$3.57, Based on 9 analyst forecasts
Low
CA$3.54
Median
CA$3.57
High
CA$3.68
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
9 Wall Street analysts provided a forecast for the next 12 months for NRX.CA. The average price target is 3.57 CAD. This implies a price increase of 485.25% is expected in the next year compared to the current price of 0.61.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
84.44%
NRX.CA was analyzed by 9 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about NRX.CA.
In the previous month the buy percentage consensus was at a similar level.
NRX.CA was analyzed by 9 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
- Period
- Q1 / 2026
- EPS Estimate
- -$0.02
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 10.43%
- Number of Analysts
- 4
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
Full Analyst Estimates 2026
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | ||||||||||||
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -5.535M | -3.624M 34.53% | -4.924M -35.87% | -6.138M -24.65% | N/A | |
| EBIT YoY % growth | -50K | -30K 40.00% | -460K -1,433.33% | -110K 76.09% | -90K 18.18% | -60K 33.33% | -130K -116.67% | -5.541M -4,162.31% | -3.657M 34.00% | -5.009M -36.97% | -6.323M -26.23% | N/A 177.48% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A 11.11% | -0.09 -5.58% | N/A 28.97% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.02 10.43% | -0.02 14.17% | -0.01 48.50% | -0.01 48.50% |
| Revenue Q2Q % growth | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
NUREXONE BIOLOGIC INC / NRX.CA Forecast FAQ
What are the consensus estimates for NUREXONE BIOLOGIC INC (NRX.CA) next earnings?
The consensus EPS estimate for the next earnings of NUREXONE BIOLOGIC INC (NRX.CA) is -0.02 CAD and the consensus revenue estimate is 0 CAD.
How many analysts have analysed NUREXONE BIOLOGIC INC (NRX.CA)?
The number of analysts covering NUREXONE BIOLOGIC INC (NRX.CA) is 9.